Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion
Sponsors
Gilead Sciences Inc., Glaxosmithkline Research & Development Limited, Taiho Oncology Inc., Catharina Ziekenhuis Stichting
Conditions
Metastatic Colorectal Cancer (mCRC)Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerResectable peritoneal metastases of a colorectal originSolid Tumors
Phase 2
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
CompletedCTIS2022-500177-13-00
Start: 2023-06-02End: 2024-06-26Target: 46Updated: 2024-04-02
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors
Active, not recruitingCTIS2023-507516-12-00
Start: 2024-05-08Target: 15Updated: 2025-06-26
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for resectable colorectal peritoneal metastases: a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
Not yet recruitingCTIS2024-518570-13-00
Target: 358Updated: 2024-11-13